Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.47 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 4/20 | 0.46 |
| ▸ | GRM1 | Q13255 | 4/20 | 0.46 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | YAP1 | P46937 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8195218 | 0.88 | NAMPT (0.57) | NAMPTTNK2GRM5GRM1PDK4 | |
| SCHEMBL6042854 | 0.84 | NAMPT (0.47) | NAMPTS1PR1S1PR3TNK2GRM5 | |
| SCHEMBL16887390 | 0.83 | NAMPT (0.54) | NAMPTTNK2GRM5GRM1PDK4 | |
| SCHEMBL25936712 | 0.82 | NAMPT (0.50) | NAMPTTNK2GRM5GRM1PDK4 | |
| SCHEMBL2404304 | 0.82 | NAMPT (0.52) | NAMPTGRM5GRM1PDK4GPR119 | |
| SCHEMBL749505 | 0.82 | PPARG (0.47) | NAMPTS1PR1S1PR3TNK2GRM5 | |
| SCHEMBL6042528 | 0.82 | NAMPT (0.49) | NAMPTTNK2GRM5GRM1PDK4 | |
| SCHEMBL23267262 | 0.80 | S1PR1 (0.50) | S1PR1S1PR3PPARGPPARA | |
| SCHEMBL1366854 | 0.79 | PDK4 (0.52) | NAMPTTNK2GRM5GRM1PDK4 | |
| SCHEMBL31009246 | 0.79 | PDK4 (0.52) | NAMPTTNK2GRM5GRM1PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20220323457-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-10-13 | — | — | US | disclosed |
| EP-4045496-A1 | BIFUNCTIONAL MOLECULES CONTAINING AN E3 UBIQUITINE LIGASE BINDING MOIETY LINKED TO A BCL6 TARGETING MOIETY | Arvinas Operations, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| WO-2021077010-A1 | BIFUNCTIONAL MOLECULES CONTAINING AN E3 UBIQUITINE LIGASE BINDING MOIETY LINKED TO A BCL6 TARGETING MOIETY | ARVINAS OPERATIONS, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | BCL6, BCL6B, BCL3 | NAMPT 4087/4885S1PR1 3171/4885S1PR3 3834/4885 |
| US-20220323457-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | BCL6, BCL6B, BCL3 | NAMPT 4087/4885S1PR1 3171/4885S1PR3 3834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.